Metformin for longevity is the most-searched "anti-aging drug" that isn't actually approved for anti-aging, and 2026 hasn't changed that. Here's what the human evidence supports, where it fits next to rapamycin and NAD+ therapy, and where it doesn't.
- Metformin for longevity has no completed human trial proving it extends healthspan as of 2026 — Consider, don't assume.
- The TAME trial proposed 3,000 participants aged 65-79 and still hasn't published mortality data.
- Rapamycin and NAD+ therapy currently have more active clinical interest for longevity than metformin does.
- Metformin can blunt exercise-driven muscle and mitochondrial adaptations — a real tradeoff for lifters.
- Rebody Health doesn't prescribe metformin for longevity; it prescribes NAD+, peptides, and hormone therapy under clinician review.
Why this matters
Metformin has been a diabetes drug since 1957 in France and since 1994 in the US. Its longevity reputation comes from a side observation: diabetics on metformin sometimes outlived non-diabetics in retrospective cohort comparisons, and lab data shows it activates AMPK, a pathway also touched by caloric restriction.
That observation launched the TAME trial (Targeting Aging with Metformin), designed around 3,000 adults aged 65 to 79. As of 2026, TAME has not published the mortality or healthspan data it was built to generate. Everything downstream of that — biohacker stacks, longevity clinic upsells, podcast claims — is running ahead of the evidence, not behind it.
That gap matters if you're deciding whether metformin for longevity belongs in your own protocol next to things with more current human data, like NAD+ therapy or growth hormone peptides.
Who this is for
This is for a healthy, non-diabetic adult, usually 40 and up, already tracking biomarkers or already running a longevity stack — testosterone therapy, NAD+, a peptide or two — who keeps seeing metformin mentioned as the "cheap baseline" and wants a straight answer on whether it earns a spot.
What to look for in metformin for longevity
Human evidence, not rodent extrapolation
Most of the striking metformin-and-lifespan headlines come from mouse and nematode studies, not people. Rodent lifespan extension does not reliably translate to humans — insulin-like signaling and metabolic rate differ enough that a positive mouse result is a hypothesis generator, not proof.
A clinician reviewing your labs before prescribing off-label
Metformin for a non-diabetic is an off-label use, which means it should come with a prescriber checking kidney function, B12 status, and current medications first, not a script filled without bloodwork.
Baseline testing before you add anything new
If you're already running hormone therapy or peptides, a baseline panel tells you whether a new compound is helping or just adding noise. An at-home hormone testing kit before a telehealth consultation gives you a number to compare against three months later, instead of guessing from how you feel.
How it interacts with training
A 2019 study (Konopka et al.) found metformin blunted the aerobic and mitochondrial adaptations from an exercise program in older adults. If you're lifting or training hard for longevity, this is the tradeoff that gets left out of most metformin threads.
Nutrient monitoring over years, not months
Long-term metformin use is linked to B12 and folate depletion. This isn't a dealbreaker, but it's a reason to recheck labs annually, not just at the start.
Fit with what you're already taking
Metformin, rapamycin, NAD+, and GH peptides all touch overlapping metabolic pathways. Stacking without a clinician mapping the combination is how people end up with GI distress and no clear signal on what's working.
Get clinician input before you stack anything
Rebody Health reviews labs and current medications before any prescription goes out.
The longevity levers actually on the table
Metformin — the cheap incumbent
Generic metformin runs 500 mg to 2,000 mg daily in standard diabetes dosing, and it's one of the least expensive prescription drugs on the market. The catch: as of 2026, there's still no completed human trial showing it extends healthspan in non-diabetics, and roughly a quarter of new users report GI side effects like diarrhea or nausea. Verdict: Consider — only with clinician oversight and only if you accept the evidence is preliminary.
Rapamycin — the mTOR contender
Rapamycin inhibits mTOR, a pathway with a longer track record of lifespan extension across multiple species than metformin's AMPK pathway has. Interest in low-dose, intermittent rapamycin protocols has grown faster in longevity medicine circles than interest in metformin has over the past few years. The full picture, including dosing intervals and monitoring, is covered in rapamycin for longevity and healthspan support. Verdict: Consider if you want the pathway with more current attention, still under clinician supervision.
NAD+ therapy — the energy-first pick
NAD+ declines with age, and repletion through injections is the more immediately felt option on this list — clients report changes in energy and mental clarity within weeks rather than the theoretical, years-out payoff metformin is chasing. Details on dosing formats and what to expect are in NAD+ injections for energy and mental clarity. Verdict: Buy if your primary complaint is fatigue or brain fog rather than long-horizon lifespan extension.
Sermorelin and other GH peptides — the growth-hormone route
Sermorelin stimulates your own growth hormone release rather than replacing it directly, which is a different mechanism entirely from metformin's glucose-and-AMPK angle. It's a reasonable pick if your goals lean toward body composition and recovery alongside longevity. Verdict: Consider for adults with documented low GH signaling, not as a general anti-aging add-on.
Epithalon — the telomere long shot
Epithalon is studied for telomerase activity and circadian regulation, but the human evidence base is thinner than for NAD+ or rapamycin. Verdict: Wait until more human data lands, unless you're specifically tracking telomere-related markers with a clinician.
What to avoid
- Ordering metformin from unlicensed online sellers without a prescription. No lab review means no one is watching kidney function or B12 levels.
- Treating mouse lifespan studies as human proof. A 20% lifespan extension in nematodes is not a promise for you.
- Stacking metformin into a hard training block and expecting strength gains. The exercise-adaptation research above says the opposite may happen.
Verdict comparison
| Option | Mechanism | Human evidence stage | Monitoring needed | Verdict |
|---|---|---|---|---|
| Metformin | AMPK activation | Pre-TAME, no completed outcome trial | Kidney function, B12, folate | Consider |
| Rapamycin | mTOR inhibition | Growing interest, intermittent dosing studied | Lipids, immune markers | Consider |
| NAD+ therapy | NAD+ repletion | Symptom-level evidence, felt short-term | Baseline energy/clarity tracking | Buy |
| Sermorelin | GH stimulation | Established for GH deficiency | IGF-1 levels | Consider |
| Epithalon | Telomerase/circadian | Early, mostly preclinical | Limited human monitoring standards | Wait |
FAQ
What is metformin for longevity and does it work?
Metformin for longevity refers to off-label use of the diabetes drug to potentially slow aging via AMPK activation. As of 2026, no completed human trial has proven it extends healthspan or lifespan in non-diabetics.
Is metformin FDA-approved for anti-aging in 2026?
No. Metformin is FDA-approved only for type 2 diabetes and related metabolic conditions. Any longevity use is off-label and requires a prescriber willing to write it outside that approved indication.
How does metformin compare to rapamycin for longevity?
Rapamycin targets mTOR and has a longer cross-species lifespan-extension track record than metformin's AMPK pathway. Metformin is cheaper and more established for metabolic use, but the longevity case for rapamycin currently draws more clinical interest.
Can a healthy, non-diabetic adult get a metformin prescription?
Some clinicians will prescribe it off-label after reviewing kidney function and full labs, but it isn't a guaranteed or standard prescription for non-diabetics. Expect bloodwork before and monitoring after.
Does metformin cause muscle loss or blunt gym gains?
Research including a 2019 study by Konopka and colleagues found metformin blunted aerobic and mitochondrial adaptations to exercise training in older adults. It doesn't cause muscle loss outright, but it can dampen training response.
What are the side effects of long-term metformin use?
Gastrointestinal issues like diarrhea and nausea affect roughly a quarter of new users, and long-term use is linked to B12 and folate depletion. Annual lab monitoring catches the nutrient issue before it becomes symptomatic.
Is NAD+ therapy better than metformin for energy?
For felt energy and mental clarity, NAD+ therapy has a faster, more immediate effect profile than metformin, which is working on a much longer, still-unproven longevity timeline.
How much does metformin cost?
Generic metformin is one of the least expensive prescription drugs on the market, commonly available for a low monthly cost without insurance. Cost is rarely the barrier — prescription access and lab monitoring are.
One last thing
Metformin's origin story predates its diabetes approval by centuries: it's derived from Galega officinalis, French lilac, an herbal remedy used for diabetes-like symptoms long before the compound was isolated and approved in France in 1957. The "ancient natural remedy" framing you'll see in some longevity content is technically true and also 70 years behind where the actual clinical question sits in 2026.